Crossover trial of gabapentin and memantine as treatment for acquired nystagmus.Ann Neurol. 2010 May; 67(5):676-80.AN
Abstract
We conducted a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patients (aged 28-61 years; 7 female; 3 multiple sclerosis [MS]; 6 post-stroke; 1 post-traumatic). Nystagmus was pendular in 6 patients (4 oculopalatal tremor; 2 MS) and jerk upbeat, hemi-seesaw, torsional, or upbeat-diagonal in each of the others. For the group, both drugs reduced median eye speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05). Each patient improved with 1 or both drugs. Side effects included unsteadiness with gabapentin and lethargy with memantine. Both drugs should be considered as treatment for acquired forms of nystagmus.
Links
MeSH
Pub Type(s)
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Language
eng
PubMed ID
20437565
Citation
Thurtell, Matthew J., et al. "Crossover Trial of Gabapentin and Memantine as Treatment for Acquired Nystagmus." Annals of Neurology, vol. 67, no. 5, 2010, pp. 676-80.
Thurtell MJ, Joshi AC, Leone AC, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol. 2010;67(5):676-80.
Thurtell, M. J., Joshi, A. C., Leone, A. C., Tomsak, R. L., Kosmorsky, G. S., Stahl, J. S., & Leigh, R. J. (2010). Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Annals of Neurology, 67(5), 676-80. https://doi.org/10.1002/ana.21991
Thurtell MJ, et al. Crossover Trial of Gabapentin and Memantine as Treatment for Acquired Nystagmus. Ann Neurol. 2010;67(5):676-80. PubMed PMID: 20437565.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Crossover trial of gabapentin and memantine as treatment for acquired nystagmus.
AU - Thurtell,Matthew J,
AU - Joshi,Anand C,
AU - Leone,Alice C,
AU - Tomsak,Robert L,
AU - Kosmorsky,Gregory S,
AU - Stahl,John S,
AU - Leigh,R John,
PY - 2010/5/4/entrez
PY - 2010/5/4/pubmed
PY - 2010/5/19/medline
SP - 676
EP - 80
JF - Annals of neurology
JO - Ann Neurol
VL - 67
IS - 5
N2 - We conducted a masked, crossover, therapeutic trial of gabapentin (1,200mg/day) versus memantine (40 mg/day) for acquired nystagmus in 10 patients (aged 28-61 years; 7 female; 3 multiple sclerosis [MS]; 6 post-stroke; 1 post-traumatic). Nystagmus was pendular in 6 patients (4 oculopalatal tremor; 2 MS) and jerk upbeat, hemi-seesaw, torsional, or upbeat-diagonal in each of the others. For the group, both drugs reduced median eye speed (p < 0.001), gabapentin by 32.8% and memantine by 27.8%, and improved visual acuity (p < 0.05). Each patient improved with 1 or both drugs. Side effects included unsteadiness with gabapentin and lethargy with memantine. Both drugs should be considered as treatment for acquired forms of nystagmus.
SN - 1531-8249
UR - https://www.unboundmedicine.com/medline/citation/20437565/Crossover_trial_of_gabapentin_and_memantine_as_treatment_for_acquired_nystagmus_
L2 - https://doi.org/10.1002/ana.21991
DB - PRIME
DP - Unbound Medicine
ER -